The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.